Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on human non-small cell lung cancer through EGFR signaling pathway

被引:0
作者
Wang, Bin [1 ]
Cui, Enhai [1 ]
Lu, Huadong [1 ]
Li, Xiaoyong [1 ]
机构
[1] Cent Hosp Huzhou, Dept Resp Med, Huzhou 313000, Zhejiang, Peoples R China
关键词
Cocultured dendritic cells; cytokine-induced killer cells; human non small cell lung cancer; RANDOMIZED PHASE-II; 1ST-LINE TREATMENT; CHEMOTHERAPY; MAINTENANCE; COMBINATION; ERLOTINIB; THERAPY; TRIAL; IMMUNOTHERAPY; CONTINUATION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The death rates of lung cancer have ranked first in the world. Many patients are at advanced stage when diagnosed; therefore, they miss optimal operative period. And some patients cannot endure radiotherapy or chemotherapy. The present study investigated the antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on human non small cell lung cancer (NSCLC) and the potential underlying mechanisms. Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells suppressed the cell proliferation, increased the cytotoxicity, induced the apoptosis and promoted caspase-3/9 activities in NSCLC. Meanwhile, the effects of cocultured dendritic cells and cytokine-induced killer cells suppressed the protein expression of TGF-beta, inhibited IL-4 activity, enhanced IL-10 and PGE-2 activities and activated the protein expression of IFN-gamma and suppressed EGFR protein expression of NSCLC. This study provides a theoretical and experimental basis for clinical immunotherapy using the effect of cocultured dendritic cells and cytokine-induced killer cells on NSCLC through activating of caspases, IL-10 activity, PGE-2, IFN-gamma and EGFR expression, and suppression of IL-4 activity and TGF-beta protein expression.
引用
收藏
页码:10906 / 10913
页数:8
相关论文
共 32 条
[1]   A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study† [J].
Aerts, J. G. ;
Codrington, H. ;
Lankheet, N. A. G. ;
Burgers, S. ;
Biesma, B. ;
Dingemans, A. -M. C. ;
Vincent, A. D. ;
Dalesio, O. ;
Groen, H. J. M. ;
Smit, E. F. .
ANNALS OF ONCOLOGY, 2013, 24 (11) :2860-2865
[2]   Profiling of primary peripheral blood-and monocyte-derived dendritic cells using monoclonal antibodies from the HLDA10 Workshop in Wollongong, Australia [J].
Autenrieth, Stella E. ;
Grimm, Sabrina ;
Rittig, Susanne Malaika ;
Grunebach, Frank ;
Gouttefangeas, CeCile ;
Bhring, Hans-JoRg .
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2015, 4
[3]   Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study [J].
Belani, Chandra P. ;
Brodowicz, Thomas ;
Ciuleanu, Tudor E. ;
Krzakowski, Maciej ;
Yang, Sung Hyun ;
Franke, Fabio ;
Cucevic, Branka ;
Madhavan, Jayaprakash ;
Santoro, Armando ;
Ramlau, Rodryg ;
Liepa, Astra M. ;
Visseren-Grul, Carla ;
Peterson, Patrick ;
John, William J. ;
Zielinski, Christoph C. .
LANCET ONCOLOGY, 2012, 13 (03) :292-299
[4]   Prospective validatioon obtained in a similar group of patients and with similar high throughput biological tests failed to confirm signatures for prediction of response to chemotherapy and survival in advanced NSCLC: a prospective study from the European Lung Cancer Working Party [J].
Berghmans, Thierry ;
Ameye, Lieveke ;
Lafitte, Jean-Jacques ;
Colinet, Benoit ;
Cortot, Alexis ;
Toth, Ingrid Cs ;
Holbrechts, Stephane ;
Lecomte, Jacques ;
Mascaux, Celine ;
Meert, Anne-Pascale ;
Paesmans, Marianne ;
Richez, Michel ;
Scherpereel, Arnaud ;
Tulippe, Christian ;
Willems, Luc ;
Dernies, Tiffany ;
Leclercq, Nathalie ;
Sculier, Jean-Paul .
FRONTIERS IN ONCOLOGY, 2015, 4
[5]   Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients With First-Line Non-Small Cell Lung Cancer Treated With Chemotherapy With or Without Bevacizumab [J].
Claret, Laurent ;
Gupta, Manish ;
Han, Kelong ;
Joshi, Amita ;
Sarapa, Nenad ;
He, Jing ;
Powell, Bob ;
Bruno, Rene .
JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (03) :253-257
[6]  
Gjomarkaj M, 1997, EUR RESPIR J, V10, P592
[7]   Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial [J].
Gridelli, Cesare ;
Bennouna, Jaafar ;
de Castro, Javier ;
Dingemans, Anne-Marie C. ;
Griesinger, Frank ;
Grossi, Francesco ;
Rossi, Antonio ;
Thatcher, Nick ;
Wong, Elaine K. ;
Langer, Corey .
CLINICAL LUNG CANCER, 2011, 12 (06) :407-411
[8]   Effectiveness and Safety of Chemotherapy Combined with Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cells in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis [J].
Han, Rui-xian ;
Liu, Xu ;
Pan, Pan ;
Jia, Ying-jie ;
Yu, Jian-chun .
PLOS ONE, 2014, 9 (09)
[9]   Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes [J].
Hayashi, T ;
Hideshima, T ;
Akiyama, M ;
Rajo, N ;
Richardson, P ;
Chauhan, D ;
Anderson, KC .
BLOOD, 2003, 102 (04) :1435-1442
[10]   Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients [J].
Huang, Ang ;
Zhang, Bo ;
Wang, Bo ;
Zhang, Fan ;
Fan, Ke-Xing ;
Guo, Ya-Jun .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (09) :1439-1451